The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Prioritization of cancer therapeutic targets using CRISPR–Cas9 screens
Open accessPublished version of a preprint
Abstract
Functional genomics approaches can overcome limitations-such as the lack of identification of robust targets and poor clinical efficacy-that hamper cancer drug development. Here we performed genome-scale CRISPR-Cas9 screens in 324 human cancer cell lines from 30 cancer types and developed a data-driven framework to prioritize candidates for cancer therapeutics. We integrated cell fitness effects with genomic biomarkers and target tractability for drug development to systematically prioritize new targets in defined tissues and genotypes. We verified one of our most promising dependencies, the Werner syndrome ATP-dependent helicase, as a synthetic lethal target in tumours from multiple cancer types with microsatellite instability. Our analysis provides a resource of cancer dependencies, generates a framework to prioritize cancer drug targets and suggests specific new targets. The principles described in this study can inform the initial stages of drug development by contributing to a new, diverse and more effective portfolio of cancer drug targets.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“the MSI that often leads to cancer simultaneously makes the inhibition of Werner syndrome ATP-dependent helicase (WRN) lethal to the tumor cells62,63”
From The origins and genetic interactions of KRAS mutations are allele- and tissue-specific (2021) · cites this paper as [62]
In the citing paper
“''Fitness Scores'' that were calculated from large-scale genome-wide CRISPR/Cas9 screens across 31 independent CRC cell lines and represent a quantitative measure of the reduction of cell viability elicited by a gene inactivation via CRISPR/Cas9 (https://score.depmap.sanger.ac.uk) (Behan et al., 2019;van der Meer et al., 2019).”
From Degradation of CCNK/CDK12 is a druggable vulnerability of colorectal cancer (2021) · cites this paper as Behan et al., 2019
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
limma powers differential expression analyses for RNA-sequencing and microarray studies
Ritchie, M. E., Phipson, B., Wu, D., Hu, Y., Law, C. W., Shi, W., & Smyth, G. K. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv007 · Cited by 40,458
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D., & Bray, F. (2015) · International Journal of Cancer · doi:10.1002/ijc.29210 · Cited by 28,766
Differential expression analysis for sequence count data
Anders, S., & Huber, W. (2010) · Genome Biology · doi:10.1186/gb-2010-11-10-r106 · Cited by 15,581
Statistical significance for genomewide studies
Storey, J. D., & Tibshirani, R. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1530509100 · Cited by 9,692
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
voom: precision weights unlock linear model analysis tools for RNA-seq read counts
Law, C. W., Chen, Y., Shi, W., & Smyth, G. K. (2014) · Genome Biology · doi:10.1186/gb-2014-15-2-r29 · Cited by 6,155
Genome-scale CRISPR-Cas9 knockout screening in human cells
Shalem, O., Sanjana, N. E., Hartenian, E., Shi, X., Scott, D. A., Mikkelsen, T. S., Heckl, D., Ebert, B. L., Root, D. E., Doench, J. G., et al. (2014) · Science · doi:10.1126/science.1247005 · Cited by 5,234
Zehir, A., Benayed, R., Shah, R. H., Syed, A., Middha, S., Kim, H. R., Srinivasan, P., Gao, J., Chakravarty, D., Devlin, S. M., et al. (2017) · Nature Medicine · doi:10.1038/nm.4333 · Cited by 3,380 · cited 1×
“Most patients however do not benefit from such targeted therapies in part due to limited knowledge of candidate targets(Zehir et al. 2017).”
Defining a Cancer Dependency Map
Tsherniak, A., Vazquez, F., Montgomery, P. G., Weir, B. A., Kryukov, G., Cowley, G. S., Gill, S., Harrington, W. F., Pantel, S., Krill-Burger, J. M., et al. (2017) · Cell · doi:10.1016/j.cell.2017.06.010 · Cited by 3,276
Cited by
Sorted by citations
Items 401–500 of 999
Ferroptosis: A Specific Vulnerability of RAS-Driven Cancers?
Andreani, C., Bartolacci, C., & Scaglioni, P. P. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.923915 · Cited by 26
Lee, H.-M., Wright, W. C., Pan, M., Low, J. A., Currier, D. G., Fang, J., Singh, S. V., Nance, S., Delahunty, I. M., Kim, Y., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-43134-0 · Cited by 23
Mei, S., Alchahin, A. M., Embaie, B. T., Gavriliuc, I. M., Verhoeven, B. M., Zhao, T., Li, X., Jeffries, N. E., Pepich, A., Sarkar, H., et al. (2024) · JCI Insight · doi:10.1172/jci.insight.173337 · Cited by 26
FANCJ promotes PARP1 activity during DNA replication that is essential in BRCA1 deficient cells
Cong, K., MacGilvary, N. J., Lee, S., MacLeod, S. G., Calvo, J. A., Peng, M., Kousholt, A. N., Day, T. A., & Cantor, S. B. (2024) · Nature Communications · doi:10.1038/s41467-024-46824-5 · Cited by 23
Zong, D., Koussa, N. C., Cornwell, J. A., Pankajam, A. V., Kruhlak, M. J., Wong, N., Chari, R., Cappell, S. D., & Nussenzweig, A. (2023) · Genes & Development · doi:10.1101/gad.351085.123 · Cited by 23
Targeting pan-essential pathways in cancer with cytotoxic chemotherapy: challenges and opportunities
Rudd, S. G. (2023) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-023-04562-3 · Cited by 22
Synthetic lethality in cancer drug discovery: challenges and opportunities
Gonçalves, E., Ryan, C. J., & Adams, D. J. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01273-7 · Cited by 27
Self-citationZikmund, T., Paszeková, H., Kokavec, J., Kerbs, P., Thakur, S., Turková, T., Tauchmanová, P., Greif, P. A., & Stopka, T. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21062073 · Cited by 23
Designing custom CRISPR libraries for hypothesis-driven drug target discovery
Iyer, V. S., Jiang, L., Shen, Y., Boddul, S. V., Panda, S. K., Kasza, Z., Schmierer, B., & Wermeling, F. (2020) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2020.08.009 · Cited by 21
Personalized cancer therapy prioritization based on driver alteration co-occurrence patterns
Mateo, L., Duran‐Frigola, M., Gris‐Oliver, A., Palafox, M., Scaltriti, M., Razavi, P., Chandarlapaty, S., Arribas, J., Bellet, M., Serra, V., et al. (2020) · Genome Medicine · doi:10.1186/s13073-020-00774-x · Cited by 22
Li, Y., Xiao, X., Chen, H., Chen, Z. B., Hu, K., & Yin, D. (2020) · PubMed Central · Cited by 22
Re-defining synthetic lethality by phenotypic profiling for precision oncology
Akimov, Y. A., & Aittokallio, T. A. (2021) · Cell chemical biology · doi:10.1016/j.chembiol.2021.01.026 · Cited by 20
The landscape of metabolic pathway dependencies in cancer cell lines
Joly, J. H., Chew, B. T. L., & Graham, N. A. (2021) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1008942 · Cited by 25
Ma, Y., Kang, B., Li, S., Xie, G., Bi, J., Li, F., An, G., Liu, B., Li, J., Shen, Y., et al. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.06.011 · Cited by 22
Ngoi, N. Y. L., Westin, S. N., & Yap, T. A. (2022) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000867 · Cited by 23
A comprehensive overview of CRISPR/Cas 9 technology and application thereof in drug discovery
Khurana, A., Sayed, N., Singh, V., Khurana, I., Allawadhi, P., Rawat, P. S., Navik, U., Pasumarthi, S. K., Bharani, K. K., & Weiskirchen, R. (2022) · Journal of Cellular Biochemistry · doi:10.1002/jcb.30329 · Cited by 22
Chen, Y., & Wang, X. (2022) · Bioinformatics · doi:10.1093/bioinformatics/btac681 · Cited by 22
INPP5A phosphatase is a synthetic lethal target in GNAQ and GNA11-mutant melanomas
Elbatsh, A. M. O., Amin‐Mansour, A., Haberkorn, A., Textor, C., Ebel, N., Renard, E., Koch, L. M., Groenveld, F. C., Piquet, M., Naumann, U., et al. (2024) · Nature Cancer · doi:10.1038/s43018-023-00710-z · Cited by 23
PSMD12 promotes breast cancer growth via inhibiting the expression of pro-apoptotic genes
Du, X., Shen, X., Dai, L., Bi, F., Zhang, H., & Lu, C. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.03.095 · Cited by 24
TargetDB: A target information aggregation tool and tractability predictor
Cesco, S. D., Davis, J. B., & Brennan, P. E. (2020) · PLoS ONE · doi:10.1371/journal.pone.0232644 · Cited by 22
Szalai, B., & Veres, D. V. (2023) · Frontiers in Systems Biology · doi:10.3389/fsysb.2023.1126044 · Cited by 21
Multimodal stimulation screens reveal unique and shared genes limiting T cell fitness
Lin, C., Levy, P. L., Alflen, A., Apriamashvili, G., Ligtenberg, M. A., Vredevoogd, D. W., Bleijerveld, O. B., Alkan, F., Malka, Y., Hoekman, L., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.02.016 · Cited by 21
Yazdi, Z. F., Roshannezhad, S., Sharif, S., & Abbaszadegan, M. R. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05908-y · Cited by 22
Tseng, Y., & Boehm, J. S. (2019) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2019.02.007 · Cited by 21
Felisberto‐Rodrigues, C., Thomas, J. C., McAndrew, C., Bihan, Y. L., Burke, R., Workman, P., & van Montfort, R. L. M. (2019) · Biochemical Journal · doi:10.1042/bcj20190383 · Cited by 23
Global View of Candidate Therapeutic Target Genes in Hormone-Responsive Breast Cancer
Salvati, A., Gigantino, V., Nassa, G., Cappa, V. M., Ventola, G. M., Cracas, D. G. C., Mastrocinque, R., Rizzo, F. M., Tarallo, R., Weisz, A., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21114068 · Cited by 21
Aregger, M., Xing, K., & Gonatopoulos-Pournatzis, T. (2021) · Nature Protocols · doi:10.1038/s41596-021-00595-1 · Cited by 22
Chen, X., Li, Y., Zhu, F., Xu, X., Estrella, B., Pazos, M. A., McGuire, J. T., Karagiannis, D., Sahu, V., Mustafokulov, M., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-39990-5 · Cited by 23
Engineering CRISPR/Cas9 therapeutics for cancer precision medicine
Sharma, A. K., & Giri, A. K. (2024) · Frontiers in Genetics · doi:10.3389/fgene.2024.1309175 · Cited by 23
Li, J., Liu, W., Mojumdar, K., Kim, H., Zhou, Z., Ju, Z., Kumar, S. V., Ng, P. K., Chen, H., Davies, M. A., et al. (2024) · Nature Cancer · doi:10.1038/s43018-024-00817-x · Cited by 23
Leto, S. M., Grassi, E., Avolio, M., Vurchio, V., Cottino, F., Ferri, M., Zanella, E. R., Borgato, S., Corti, G., di Blasio, L., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-51909-2 · Cited by 20
Self-citationThe integrated stress response drives MET oncogene overexpression in cancers
Cerqua, M., Foiani, M., Boccaccio, C., Comoglio, P. M., & Altintas, D. M. (2025) · The EMBO Journal · doi:10.1038/s44318-024-00338-4 · Cited by 20
Pharmacogenomics for immunotherapy and immune-related cardiotoxicity
Lal, J. C., Eng, C., & Cheng, F. (2020) · Human Molecular Genetics · doi:10.1093/hmg/ddaa137 · Cited by 21
Versatile modification of the CRISPR/Cas9 ribonucleoprotein system to facilitate in vivo application
Sun, B., Chen, H., & Gao, X. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.08.007 · Cited by 20
In vivo inducible reverse genetics in patients’ tumors to identify individual therapeutic targets
Carlet, M., Völse, K., Vergalli, J., Becker, M., Herold, T., Arner, A., Senft, D., Jurinović, V., Liu, W., Gao, Y., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25963-z · Cited by 19
In vitro breast cancer models for studying mechanisms of resistance to endocrine therapy
Cheng, G. J., Leung, E. Y., & Singleton, D. C. (2022) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2022.00084 · Cited by 22
Jin, P., Jin, Q., Wang, X., Zhao, M., Dong, F., Jiang, G., Li, Z., Shen, J., Zhang, W., Wu, S., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1618 · Cited by 22
Woods, M. L., Weiß, A., Sokòl, A. M., Graumann, J., Boettger, T., Richter, A. M., SCHERMULY, R. T., & Dammann, R. (2022) · Cancer Gene Therapy · doi:10.1038/s41417-022-00513-x · Cited by 18
Altintas, D. M., Gallo, S., Basilico, C., Cerqua, M., Bocedi, A., Vitacolonna, A., Botti, O., Casanova, E., Rancati, I., Milanese, C., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232012427 · Cited by 20
Z-DNA enhances immunotherapy by triggering death of inflammatory cancer-associated fibroblasts
Herbert, A. G., & Balachandran, S. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005704 · Cited by 20
Goruppi, S., Clocchiatti, A., Bottoni, G., Cicco, E. D., Ma, M., Tassone, B., Neel, V., Demehri, S., Simon, C., & Dotto, G. P. (2023) · Nature Communications · doi:10.1038/s41467-023-36410-6 · Cited by 22
CRISPR activation screens identify the SWI/SNF ATPases as suppressors of ferroptosis
Bhat, K. P., Vijay, J., Vilas, C. K., Asundi, J., Zou, J., Lau, T., Cai, X. T., Ahmed, M., Kabza, M., Weng, J., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114345 · Cited by 23
Discovery of Small Molecule Antagonists of the USP5 Zinc Finger Ubiquitin-Binding Domain
Mann, M. K., Franzoni, I., de Freitas, R. F., Tempel, W., Houliston, S., Smith, L., Vedadi, M., Arrowsmith, C. H., Harding, R., & Schapira, M. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00988 · Cited by 17
Functional genomics approaches to improve pre‐clinical drug screening and biomarker discovery
Nguyen, L. V., & Caldas, C. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202013189 · Cited by 19
Paralogous synthetic lethality underlies genetic dependencies of the cancer-mutated gene STAG2
Bailey, M. L., Tieu, D. D., Habsid, A., Tong, A. H. Y., Chan, K., Moffat, J., & Hieter, P. (2021) · Life Science Alliance · doi:10.26508/lsa.202101083 · Cited by 19
Are CRISPR Screens Providing the Next Generation of Therapeutic Targets?
Vazquez, F., & Sellers, W. R. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-1784 · Cited by 19
Research on Werner Syndrome: Trends from Past to Present and Future Prospects
Tsuge, K., & Shimamoto, A. (2022) · Genes · doi:10.3390/genes13101802 · Cited by 22
Common strategies in silkworm disease resistance breeding research
Li, K., Dong, Z., & Pan, M. (2023) · Pest Management Science · doi:10.1002/ps.7454 · Cited by 20
Dong, Y., He, Q., Pei, L., Yang, M., Huang, L., Kong, J., He, W., Liu, H., Xu, S., Qin, H., et al. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-06000-x · Cited by 21
Myo-differentiation reporter screen reveals NF-Y as an activator of PAX3–FOXO1 in rhabdomyosarcoma
Sroka, M. W., Skopelitis, D. S., Vermunt, M. W., Preall, J. B., Demerdash, O. E., de Almeida, L. M. N., Chang, K., Utama, R., Gryder, B. E., Caligiuri, G., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2303859120 · Cited by 19
Li, F., Yu, J., Pan, T., Feng, H., Li, J., Yu, B., Fan, Z., Sang, Q., Chen, M., Zang, M., et al. (2023) · Advanced Science · doi:10.1002/advs.202303091 · Cited by 19
Closing in on human methylation—the versatile family of seven-β-strand (METTL) methyltransferases
Falnes, P. Ø. (2024) · Nucleic Acids Research · doi:10.1093/nar/gkae816 · Cited by 20
The application of CRISPR/Cas9–based genome-wide screening to disease research
Chen, X., Zheng, M., Lin, S., Huang, M., Chen, S., & Chen, S. (2024) · Molecular and Cellular Probes · doi:10.1016/j.mcp.2024.102004 · Cited by 21
Kloetgen, A., Duggimpudi, S., Schuschel, K., Hezaveh, K., Picard, D. J., Schaal, H., Remke, M., Klusmann, J., Borkhardt, A., McHardy, A. C., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124453 · Cited by 18
Functional Screening Techniques to Identify Long Non-Coding RNAs as Therapeutic Targets in Cancer
Lucere, K. M., O’Malley, M. M. R., & Diermeier, S. D. (2020) · Cancers · doi:10.3390/cancers12123695 · Cited by 19
Li, P., Hao, Z., Liu, H., Zhu, B., Dang, L., Ma, C., Xu, Y., Zhang, Y., Fan, D., & Sun, S. (2021) · Biology · doi:10.3390/biology10030250 · Cited by 19
Minimized double guide RNA libraries enable scale-limited CRISPR/Cas9 screensPreprint
Peets, E. M., Crepaldi, L., Zhou, Y., Allen, F., Elmentaite, R., Noell, G. G., Turner, G., Iyer, V., & Parts, L. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/859652 · Cited by 17
Evans, L., Strano, A., Tuck, E. J., Campbell, A., Smith, J. C., Hung, C., Behr, T. S., Ghetti, B. F., Falcon, B., Karakoç, E., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.08.11.246363 · Cited by 19
Self-citationBhat, S. M., Palepu, K., Hong, L., Mao, J., Ye, T., Iyer, R., Zhao, L., Chen, T., Vincoff, S., Watson, R., et al. (2024) · bioRxiv · doi:10.1101/2023.06.26.546591 · Cited by 90
Jiang, J., Ma, Y., Yang, L., Ma, S., Yu, Z., Ren, X., Kong, X., Zhang, X., Li, D., & Liu, Z. (2024) · Nucleic Acids Research · doi:10.1093/nar/gkae993 · Cited by 19
Engineering novel CRISPRi repressors for highly efficient mammalian gene regulation
Kristof, A., Karunakaran, K., Allen, C., Mizote, P., Briggs, S., Jian, Z., Nash, P., & Blazeck, J. (2025) · Genome biology · doi:10.1186/s13059-025-03640-4 · Cited by 18
Li, H., Cheng, Y., Zhou, Z.-W., Long, H., Luo, H., Wen, D., Cheng, L. Z., & Gao, L. (2021) · Oncology Letters · doi:10.3892/ol.2021.13126 · Cited by 18
Serelli-Lee, V., Ito, K., Koibuchi, A., Tanigawa, T., Ueno, T., Matsushima, N., & Imai, Y. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12050669 · Cited by 22
SWAN pathway-network identification of common aneuploidy-based oncogenic drivers
Bowers, R. R., Jones, C. M., Paz, E. A., Barrows, J. K., Armeson, K. E., Long, D. T., & Delaney, J. R. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkac200 · Cited by 18
Zhang, Y., Li, J., Zhou, Y., Li, Z., Peng, C., Pei, H., & Zhu, W. (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-0769 · Cited by 18
CRISPR/Cas9-based genome editing for multimodal synergistic cancer nanotherapy
Pu, Y., Wu, W., Xiang, H., Chen, Y., & Xu, H. (2022) · Nano Today · doi:10.1016/j.nantod.2022.101734 · Cited by 18
AP1/Fra1 confers resistance to MAPK cascade inhibition in pancreatic cancer
Schneeweis, C., Diersch, S., Hassan, Z., Krauß, L., Schneider, C., Lucarelli, D., Falcomatà, C., Steiger, K., Öllinger, R., Krämer, O. H., et al. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04638-y · Cited by 19
Ahmed, I., Yang, S., Ogden, S., Zhang, W., Li, Y., & Sharrocks, A. D. (2023) · eLife · doi:10.7554/elife.80840 · Cited by 18
Uncovering therapeutic opportunities in the clinical development of antibody‐drug conjugates
Nieto‐Jiménez, C., Sanvicente, A., Díaz‐Tejeiro, C., Moreno, V., Lorenzo, A. L. D. S., Calvo, E., Martínez‐López, J., Pérez‐Segura, P., & Ocaña, A. (2023) · Clinical and Translational Medicine · doi:10.1002/ctm2.1329 · Cited by 18
Chemical Proteomics–Guided Discovery of Covalent Ligands for Cancer Proteins
Zhang, X., & Cravatt, B. F. (2024) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-061421-041946 · Cited by 19
Johnson, S. S., Liu, D., Ewald, J. T., Robles-Planells, C., Pulliam, C. F., Christensen, K. A., Bayanbold, K., Wels, B., Solst, S. R., O'Dorisio, M. S., et al. (2024) · Cancer Biology & Therapy · doi:10.1080/15384047.2024.2382524 · Cited by 18
Fragliasso, V., Verma, A., Manzotti, G., Tameni, A., Bareja, R., Heavican, T. B., Iqbal, J., Wang, R., Fiore, D., Mularoni, V., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0754-8 · Cited by 18
Dolce, V., Dusi, S., Giannattasio, M., Joseph, C. R., Fumasoni, M., & Branzei, D. (2022) · Genes & Development · doi:10.1101/gad.349207.121 · Cited by 16
Sui, Q., Zhou, Y., Li, M., Wang, D., Cui, R., Cai, X., Liu, J., Wang, X., Teng, D., Zhou, J., et al. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.117039 · Cited by 17
A multilineage screen identifies actionable synthetic lethal interactions in human cancers
Fong, S. H., Kuenzi, B. M., Mattson, N. M., Lee, J. J. Y., Sanchez, K. S., Bojorquez-Gomez, A., Ford, K. M., Munson, B. P., Licon, K., Bergendahl, S., et al. (2024) · Nature Genetics · doi:10.1038/s41588-024-01971-9 · Cited by 18
The transcriptomic architecture of common cancers reflects synthetic lethal interactions
Haider, S. A., Brough, R., Madera, S., Iacovacci, J., Gulati, A., Wicks, A. J., Alexander, J. J., Pettitt, S. J., Tutt, A. N. J., & Lord, C. J. (2025) · Nature Genetics · doi:10.1038/s41588-025-02108-2 · Cited by 17
Chan, P. Y., Alexander, D., Mehta, I., Matsuyama, L. S. A. S., Harle, V. J., Olvera-León, R., Park, J. S., Arriaga-González, F. G., van der Weyden, L., Cheema, S., et al. (2025) · Nature Genetics · doi:10.1038/s41588-025-02222-1 · Cited by 19
Self-citationTargeting FSP1 to induce ferroptosis in chromophobe renal cell carcinoma
Salem, S., Han, T., Alchoueiry, M., Mahmoud, N., Bzeih, W., Chami, J., Khabibullin, D., Mansour, H., Tang, Y., Ho, T. H., et al. (2025) · Oncogene · doi:10.1038/s41388-025-03562-2 · Cited by 20
Discovery and characterization of potent And‐1 inhibitors for cancer treatment
Li, J., Zhang, Y., Sun, J., Chen, L., Gou, W., Chen, C., Zhou, Y., Li, Z., Chan, D. W., Huang, R., et al. (2021) · Clinical and Translational Medicine · doi:10.1002/ctm2.627 · Cited by 17
Wang, Q., Li, J., Zhu, J., Mao, J., Duan, C., Liang, X., Zhu, L., Zhu, M., Zhang, Z., Lin, F., et al. (2022) · Clinical and Translational Medicine · doi:10.1002/ctm2.882 · Cited by 17
Delineation of Pathogenomic Insights of Breast Cancer in Young Women
Paul, A. M., George, B., Saini, S., Pillai, M. R., Toi, M., Costa, L., & Kumar, R. (2022) · Cells · doi:10.3390/cells11121927 · Cited by 17
Lebedev, T. D., Buzdin, A. A., Khabusheva, E., Spirin, P., Suntsova, M., Sorokin, M., Попенко, В. И., Рубцов, П. М., & Prassolov, V. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23147724 · Cited by 17
Zhou, C., Huang, H., Wang, Y., Sendinc, E., & Shi, Y. (2022) · Cell Discovery · doi:10.1038/s41421-022-00470-7 · Cited by 17
Multi-omics approach to identifying isoform variants as therapeutic targets in cancer patients
Shaw, T. I., Zhao, B., Li, Y., Wang, H., Wang, L., Manley, B. J., Stewart, P. A., & Karolak, A. M. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1051487 · Cited by 16
Targeting ARID1A-Deficient Cancers: An Immune-Metabolic Perspective
Lebedev, T. D., Kousar, R., Patrick, B., Usama, M., Lee, M.-K., Tan, M., & Li, X. (2023) · Cells · doi:10.3390/cells12060952 · Cited by 17
Reproducibility metrics for context-specific CRISPR screens
Billmann, M., Ward, H. N., Aregger, M., Costanzo, M., Andrews, B., Boone, C. M., Moffat, J., & Myers, C. L. (2023) · Cell Systems · doi:10.1016/j.cels.2023.04.003 · Cited by 16
Shi, J., Jiao, T., Guo, Q., Weng, W., Ma, L., Zhang, Q., Wang, L., Zhang, J., Chen, C., Huang, Y., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-23-1356 · Cited by 18
Li, J., Yang, F., Wang, Z., Zheng, S., Zhang, S., Wang, C., He, B., Wang, J., & Wang, H. (2023) · Cell Proliferation · doi:10.1111/cpr.13590 · Cited by 17
Interaction between MED12 and ΔNp63 activates basal identity in pancreatic ductal adenocarcinoma
Maia-Silva, D., Cunniff, P. J., Schier, A. C., Skopelitis, D. S., Trousdell, M. C., Moresco, P., Gao, Y., Kechejian, V., He, X., Sahin, Y., et al. (2024) · Nature Genetics · doi:10.1038/s41588-024-01790-y · Cited by 17
Li, C., Du, X., Zhang, H., & Liu, S. (2024) · CytoJournal · doi:10.25259/cytojournal_29_2024 · Cited by 19
In silico Method in CRISPR/Cas System: An Expedite and Powerful Booster
Zhang, Y., Zhao, G., Ahmed, F. Y. H., Yi, T., Hu, S., Cai, T., & Liao, Q. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.584404 · Cited by 17
Recent advances in CRISPR technologies for genome editing
Song, M., & Koo, T. (2021) · Archives of Pharmacal Research · doi:10.1007/s12272-021-01336-4 · Cited by 18
Condorelli, D. F., Privitera, A. P., & Barresi, V. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20184652 · Cited by 17
Shimada, K., Muhlich, J. L., & Mitchison, T. J. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2019.12.13.874776 · Cited by 14
Ledidi: Designing genomic edits that induce functional activityPreprint
Schreiber, J. M., Lu, Y. Y., & Noble, W. S. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.05.21.109686 · Cited by 17
CIP2A is a prime synthetic-lethal target for BRCA-mutated cancersPreprint
Adam, S., Rossi, S. E., Moatti, N., Zompit, M. D. M., Ng, T. F., Álvarez-Quilón, A., Desjardins, J., Bhaskaran, V., Martino, G., Setiaputra, D., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.02.08.430060 · Cited by 17
Mining folded proteomes in the era of accurate structure prediction
Bayly-Jones, C., & Whisstock, J. C. (2022) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1009930 · Cited by 16
Far, B. F., Akbari, M., Habibi, M. A., Katavand, M., & Nasseri, S. (2025) · Cell Proliferation · doi:10.1111/cpr.70099 · Cited by 23
Pathway-guided architectures for interpretable AI in biological research
Zhou, Q. F., Madala, N. S., & Huang, C. L. (2025) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2025.10.063 · Cited by 18
Cell cycle progression and transmitotic apoptosis resistance promote escape from extrinsic apoptosis
Pollak, N., Lindner, A., Imig, D., Kuritz, K., Fritze, J. S., Decker, L., Heinrich, I., Stadager, J., Eisler, S. A., Stöhr, D., et al. (2021) · Journal of Cell Science · doi:10.1242/jcs.258966 · Cited by 17
Metadata
- Authors
- Behan, F. M., Iorio, F., Picco, G., Gonçalves, E., Beaver, C. M., Migliardi, G., Santos, R., Rao, Y., Sassi, F., Pinnelli, M., Ansari, R., Harper, S., Jackson, D. A., McRae, R., Pooley, R., Wilkinson, P., van der Meer, D., Dow, D., Buser-Doepner, C., Bertotti, A., Trusolino, L., Stronach, E. A., Saez-Rodriguez, J., Yusa, K., & Garnett, M. J.
- Affiliations
- Wellcome Sanger Institute (GB)
- European Bioinformatics Institute (GB)
- Candiolo Cancer Institute (IT)
- GlaxoSmithKline (United Kingdom) (GB)
- GlaxoSmithKline (United States) (US)
- Kyoto University (JP)
- Corresponding author
- Yusa, Kosuke
- Garnett, Mathew J.
- ORCID
- Venue
- Nature
- Published
- 2019-04-10
- Volume
- 568
- Issue
- 7753
- Pages
- 511-516
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2936686072
- Cited by
- 1,338
- References
- 64
- Citations by year
- 2026: 129 · 2025: 168 · 2024: 200 · 2023: 158 · 2022: 200 · 2021: 227 · 2020: 179 · 2019: 74
- FWCI
- 56.69
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Licence
- Locations
- Nature (publishedVersion)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- RePEc: Research Papers in Economics (submittedVersion)
- RWTH Publications (RWTH Aachen) (submittedVersion)
- Funders
- Wellcome Trust (C44943/A22536, SU2C-AACR-DT1213, 102696, 206194)
- Cancer Research UK (A22536, SU2C-AACR-DT1213, 102696, C44943/A22536)
- Associazione Italiana per la Ricerca sul Cancro (5X 1000, 21091, 20697, 18532)
- Stand Up To Cancer (SU2C-AACRDT1213)
- H2020 European Research Council (724748)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- cancer cell lines, synthetic lethality, microsatellite instability, cancer dependency, genomic biomarkers, anticancer drug development
- MeSH terms
- Werner Syndrome Helicase, Synthetic Lethal Mutations, Gene Editing, Animals, Female, Humans, Neoplasm Transplantation, Neoplasms, Organ Specificity, Biomarkers, Tumor, Werner Syndrome, Reproducibility of Results, Genome, Human, Cell Line, Tumor, Mice, Microsatellite Instability, Drug Discovery, Molecular Targeted Therapy, CRISPR-Cas Systems
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
